Calamos Advisors’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $523K | Buy |
+8,629
| New | +$503K | ﹤0.01% | 902 |
|
|
2025
Q2 | – | Sell |
-107,005
| Closed | -$6.53M | – | 929 |
|
|
2025
Q1 | $6.53M | Sell |
107,005
-516,993
| -83% | -$30.1M | 0.03% | 477 |
|
|
2024
Q4 | $35.3M | Hold |
623,998
| – | – | 0.15% | 152 |
|
|
2024
Q3 | $32.3M | Sell |
623,998
-18,308
| -3% | -$859K | 0.14% | 180 |
|
|
2024
Q2 | $26.7M | Sell |
642,306
-18,356
| -3% | -$821K | 0.12% | 204 |
|
|
2024
Q1 | $35.8M | Sell |
660,662
-13,107
| -2% | -$668K | 0.17% | 159 |
|
|
2023
Q4 | $34.6M | Sell |
673,769
-6,333
| -0.9% | -$332K | 0.17% | 166 |
|
|
2023
Q3 | $39.5M | Sell |
680,102
-1,511
| -0.2% | -$92.6K | 0.21% | 131 |
|
|
2023
Q2 | $43.6M | Sell |
681,613
-244,526
| -26% | -$16.4M | 0.22% | 117 |
|
|
2023
Q1 | $64.2M | Sell |
926,139
-100,851
| -10% | -$7.11M | 0.31% | 73 |
|
|
2022
Q4 | $73.9M | Sell |
1,026,990
-210,455
| -17% | -$15.9M | 0.35% | 61 |
|
|
2022
Q3 | $88M | Sell |
1,237,445
-1,453
| -0.1% | -$105K | 0.4% | 42 |
|
|
2022
Q2 | $95.4M | Buy |
1,238,898
+110,934
| +10% | +$8.45M | 0.41% | 41 |
|
|
2022
Q1 | $82.4M | Buy |
1,127,964
+147,888
| +15% | +$9.93M | 0.31% | 68 |
|
|
2021
Q4 | $61.1M | Buy |
980,076
+39,711
| +4% | +$2.33M | 0.23% | 104 |
|
|
2021
Q3 | $55.6M | Buy |
940,365
+143,994
| +18% | +$9.48M | 0.24% | 98 |
|
|
2021
Q2 | $53.2M | Buy |
796,371
+114,232
| +17% | +$7.45M | 0.24% | 97 |
|
|
2021
Q1 | $43.1M | Buy |
682,139
+11,244
| +2% | +$700K | 0.23% | 101 |
|
|
2020
Q4 | $41.6M | Sell |
670,895
-18,983
| -3% | -$1.17M | 0.24% | 110 |
|
|
2020
Q3 | $41.6M | Sell |
689,878
-45,338
| -6% | -$2.73M | 0.27% | 94 |
|
|
2020
Q2 | $43.2M | Buy |
735,216
+93,068
| +14% | +$5.57M | 0.31% | 89 |
|
|
2020
Q1 | $35.8M | Sell |
642,148
-31,818
| -5% | -$1.94M | 0.28% | 105 |
|
|
2019
Q4 | $43.3M | Buy |
673,966
+249,074
| +59% | +$14.3M | 0.21% | 133 |
|
|
2019
Q3 | $21.5M | Buy |
424,892
+26,910
| +7% | +$1.26M | 0.12% | 223 |
|
|
2019
Q2 | $18M | Buy |
397,982
+12,669
| +3% | +$590K | 0.1% | 241 |
|
|
2019
Q1 | $18.4M | Buy |
385,313
+2,420
| +0.6% | +$121K | 0.11% | 231 |
|
|
2018
Q4 | $19.9M | Buy |
382,893
+34,234
| +10% | +$1.84M | 0.13% | 214 |
|
|
2018
Q3 | $21.6M | Buy |
348,659
+25,996
| +8% | +$1.54M | 0.12% | 211 |
|
|
2018
Q2 | $17.9M | Sell |
322,663
-565,706
| -64% | -$30.6M | 0.11% | 237 |
|
|
2018
Q1 | $56.2M | Sell |
888,369
-16,376
| -2% | -$1.05M | 0.37% | 71 |
|
|
2017
Q4 | $55.4M | Buy |
904,745
+403,665
| +81% | +$25.2M | 0.28% | 65 |
|
|
2017
Q3 | $31.9M | Buy |
501,080
+192,255
| +62% | +$11.2M | 0.25% | 125 |
|
|
2017
Q2 | $17.2M | Buy |
308,825
+10,369
| +3% | +$564K | 0.13% | 214 |
|
|
2017
Q1 | $16.2M | Buy |
298,456
+150,541
| +102% | +$8.26M | 0.13% | 211 |
|
|
2016
Q4 | $8.64M | Sell |
147,915
-34,211
| -19% | -$1.87M | 0.07% | 283 |
|
|
2016
Q3 | $9.82M | Buy |
182,126
+25,374
| +16% | +$1.63M | 0.07% | 274 |
|
|
2016
Q2 | $11.5M | Buy |
156,752
+58
| +0% | +$4.1K | 0.08% | 261 |
|
|
2016
Q1 | $10M | Buy |
156,694
+9,582
| +7% | +$604K | 0.07% | 266 |
|
|
2015
Q4 | $10.1M | Hold |
147,112
| – | – | 0.06% | 269 |
|
|
2015
Q3 | $8.71M | Buy |
147,112
+50
| +0% | +$3.17K | 0.06% | 277 |
|
|
2015
Q2 | $9.79M | Sell |
147,062
-16,816
| -10% | -$1.11M | 0.06% | 268 |
|
|
2015
Q1 | $10.6M | Sell |
163,878
-391
| -0.2% | -$24.5K | 0.07% | 259 |
|
|
2014
Q4 | $9.7M | Buy |
164,269
+13,169
| +9% | +$743K | 0.06% | 268 |
|
|
2014
Q3 | $7.73M | Hold |
151,100
| – | – | 0.05% | 289 |
|
|
2014
Q2 | $7.33M | Buy |
151,100
+10,900
| +8% | +$537K | 0.05% | 293 |
|
|
2014
Q1 | $7.28M | Hold |
140,200
| – | – | 0.05% | 275 |
|
|
2013
Q4 | $7.45M | Sell |
140,200
-18,147
| -11% | -$924K | 0.05% | 270 |
|
|
2013
Q3 | $7.33M | Buy |
158,347
+7,475
| +5% | +$328K | 0.05% | 262 |
|
|
2013
Q2 | $6.74M | Buy |
+150,872
| New | +$6.55M | 0.04% | 254 |
|
Other funds holding BMY
VCM
VPM
Calamos Advisors's BMY Position: Q1 2026 in Review
Calamos Advisors opened a new position in Bristol-Myers Squibb (BMY) in Q1 2026: 8,629 shares worth $523K. The stake represents ﹤0.01% of the portfolio and ranks #902 among its holdings. This is a return to the name: Calamos Advisors previously reported a position in BMY as recently as Q1 2025.
Calamos Advisors first reported a position in BMY in Q2 2013 and has held it in 49 quarters since. The position peaked at $95.4M in Q2 2022. 2,518 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Calamos Advisors held 8,629 shares of Bristol-Myers Squibb worth $523K as of Q1 2026.
- Bristol-Myers Squibb was a new Calamos Advisors position in Q1 2026.
- Bristol-Myers Squibb made up ﹤0.01% of Calamos Advisors's portfolio in Q1 2026, its #902 holding.
- Calamos Advisors first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 49 quarters since.
- Calamos Advisors's Bristol-Myers Squibb position peaked at $95.4M in Q2 2022.
- 2,518 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Calamos Advisors's 13F filing for Q1 2026, filed 4 May 2026.